

Avanafil 2.00: The 2nd generation of PDE5-Is has begun

Industry session by THE MENARINI GROUP

Sunday, 13 March
17:45 - 19:15

Location: Room Vienna (Hall B2, level 0)

Chair: V.G. Mirone, Naples (IT)

Aims and objectives of this presentation

ED is a highly prevalent male sexual dysfunction. PDE5is are the first line treatment for ED. Despite their effectiveness, there is still a non-negligible number of patients who discontinue because of either personal or partners' sexual dissatisfaction with the chosen treatment. Avanafil is a 2nd generation PDE5-I recently approved in EU. Based on clinical results, it offers an innovative on demand solution for ED patients, providing them with a better tolerated treatment, even at the highest dosage, and a rapid & sustained efficacy allowing to respond immediately to the partner wishes without the need to plan sex in advance.

17:45 - 17:55

Introduction: The treatment of erectile dysfunction in the era of 2nd generation PDE5 inhibitors
V.G. Mirone, Naples (IT)

17:55 - 18:15

Discontinuation and dissatisfaction: The crucial impact of tolerability
G. Corona

18:15 - 18:35

Avanafil 200mg: The favourable compromise
W. Hellstrom, New Orleans (US)

18:35 - 18:55

Matching patient expectations: The contribution of avanafil in the real life setting
H. Porst, Hamburg (DE)

18:55 - 19:00

Wrap up and closure
V.G. Mirone, Naples (IT)

19:00 - 19:15

Questions and answers
V.G. Mirone, Naples (IT)